Donanemab (TRAILBLAZER-ALZ 3)
Early Symptomatic Alzheimer's Disease
Sponsor Eli Lilly
3,300 Enrollment Target
275 Trial Sites
5 Countries
June 2027 Est. Completion
About This Trial
Anti-amyloid antibody targeting N3pG amyloid for earlier-stage Alzheimer's patients.
Primary Endpoints
- iADRS score change
- Amyloid plaque clearance
Latest Update
February 2026
FDA approved Kisunla (donanemab) in July 2025. Post-marketing study confirms 35% slowing of decline at 18 months.
Lead Investigators
DR
Dr. Reisa Sperling Director, Center for Alzheimer Research, BWH